# A Study of HRS2543 in Patients With Advanced Tumors

> **NCT05068856** · PHASE1 · TERMINATED · sponsor: **Shanghai Hengrui Pharmaceutical Co., Ltd.** · enrollment: 10 (actual)

## Conditions studied

- Advanced Tumors

## Interventions

- **DRUG:** HRS2543

## Key facts

- **NCT ID:** NCT05068856
- **Lead sponsor:** Shanghai Hengrui Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-12-28
- **Primary completion:** 2024-05-15
- **Final completion:** 2024-05-15
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** R\&d strategy adjustment
- **Last updated:** 2024-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05068856

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05068856, "A Study of HRS2543 in Patients With Advanced Tumors". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05068856. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*